Xeris Pharmaceuticals

Home
United States
Chicago, IL
Xeris Pharmaceuticals

We’re a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

Pharmaceutical Company

07/14/2025

What a week!

We just got back from Children with Diabetes Friends for Life Orlando 2025 and our hearts are full. It was such an honor to spend time with so many inspiring children, adults, and families with . The energy, the support, the learning - it’s hard to put into words how special this event truly is.

A huge thank you to Children with Diabetes for creating a space where connection, learning, and community come first. We’re so grateful to be a part of it, and we can’t wait to see you all again next year! Check out some of our favorite moments below.

Address

Chicago, IL
60601

Website

http://www.xerispharma.com/

Alerts

Be the first to know and let us send you an email when Xeris Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xeris Pharmaceuticals:

Shortcuts

Want your practice to be the top-listed Clinic in Chicago?

About Xeris

Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol™ and XeriJect™ formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris’ platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol™ and XeriJect™ offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.